BM

Bernard Majoie

Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels

Description

Bernard Majoie - President @ Fournier-Majoie

Investor Profile

Bernard Majoie has made 6 investments, with 0 in the past 12 months and 33% as lead.

Stage Focus

  • Seed (50%)
  • Series B (17%)
  • Series A (17%)
  • Pre Seed (17%)

Country Focus

  • France (83%)
  • Belgium (17%)

Industry Focus

  • Biotechnology
  • Medical
  • Oncology
  • Therapeutics
  • Health Care
  • Health Diagnostics
  • Life Science
  • Neuroscience
  • Clinical Trials
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Bernard Majoie frequently co-invest with?

BNP Paribas Fortis
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 1
Doorway Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Italian Angels for Growth
Europe, Lombardia, Italy, Milan
Co-Investments: 1
Gemma Frisius Fund
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 1
Korys
Europe, Vlaams-Brabant, Belgium, Halle
Co-Investments: 1
Seventure Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
Magna Capital Partners
North America, Illinois, United States, Chicago
Co-Investments: 1
KU Leuven
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 1
LB
Europe, Ile-de-France, France, Paris
Co-Investments: 1
PMV
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 1

Which angels does Bernard Majoie often collaborate with?

CW
Europe, Vlaams-Brabant, Belgium, Leuven
Shared Deals: 1

What are some of recent deals done by Bernard Majoie?

AgenT

Paris, Ile-de-France, France

AgenT develops the first blood diagnosis to detect Alzheimer's disease from the asymptomatic stage.

BiotechnologyHealth CareHealth DiagnosticsLife ScienceNeuroscience
SeedJul 1, 2021
Amount Raised: $2,724,534
PEP-Therapy

Évry, Ile-de-France, France

Innovative peptides as targeted therapies for oncology

BiotechnologyMedicalOncologyTherapeutics
Series AApr 22, 2021
Amount Raised: $3,303,974
AgenT

Paris, Ile-de-France, France

AgenT develops the first blood diagnosis to detect Alzheimer's disease from the asymptomatic stage.

BiotechnologyHealth CareHealth DiagnosticsLife ScienceNeuroscience
Pre SeedJan 31, 2020
Amount Raised: $1,220,461
reMYND

Leuven, Vlaams-Brabant, Belgium

reMYND drives the development of disease-modifying treatments against protein misfolding disorders.

BiotechnologyClinical TrialsManufacturingMedical
Series BDec 18, 2018
Amount Raised: $13,651,023
PEP-Therapy

Évry, Ile-de-France, France

Innovative peptides as targeted therapies for oncology

BiotechnologyMedicalOncologyTherapeutics
SeedNov 16, 2017
Amount Raised: $1,413,388
PEP-Therapy

Évry, Ile-de-France, France

Innovative peptides as targeted therapies for oncology

BiotechnologyMedicalOncologyTherapeutics
SeedApr 27, 2015
Amount Raised: $1,413,886